|
Cohort1: Fovista_bevacizumab
|
| Administration route |
intravitreal injection |
| Dosage |
1.5 mg |
| Pts |
21 |
| Age |
Adult, Older_Adult |
| Adverse reactions |
3/21(Infections and infestations) |
|
|
Cohort2: Fovista_ranibizumab
|
| Administration route |
intravitreal injection |
| Dosage |
1.5 mg |
| Pts |
21 |
| Age |
Adult, Older_Adult |
| Adverse reactions |
3/21(Eye disorders; Injury, poisoning and procedural complications; Respiratory, thoracic and mediastinal disorders) |
|
|
Cohort3: Fovista_aflibercept
|
| Administration route |
intravitreal injection |
| Dosage |
1.5 mg |
| Pts |
21 |
| Age |
Adult, Older_Adult |
| Adverse reactions |
5/21(Cardiac disorders; General disorders; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified, incl cysts and polyps; Renal and urinary disorders) |
|